The global healthcare AI market was valued at US$ 4.8 billion in 2019 and is projected to reach US$ 99.5 billion by 2027. The CAGR in this time frame is estimated to be 42.8%.
The opportunity in this emerging sector is massive, and early adopters will have a distinct advantage, but pharmaceutical companies are facing challenges when it comes to AI adoption.
The Edmonton region has unique strengths in the areas of both AI research and drug discovery and this session will provide an overview of this interesting intersection and an overview of some of the exciting things taking place in the Edmonton region’s Health AI ecosystem.
WHAT ATTENDEES CAN EXPECT TO LEARN
Global strategic context – A global perspective on the intersection of AI and drug research and development and what that means for the future of this industry
Industry perspective – An industry perspective on how AI can solve some of the challenges around commercializing research and accelerate the scalability of businesses operating in this space.
Market overview – Identification and analysis some of the key problems pharmaceutical firms are facing around AI adoption (and how the Edmonton region stacks up)
· Access to talent
· Knowledge gap
· Availability of data
· Regulatory environment
Netherlands-Canada Chamber of Commerce | Wilhelminastraat 184 HS | 1054 WT Amsterdam| The Netherlands | +31 (70) 2210 555 | email@example.com